ESCRS - Anti-vegf therapy ;
ESCRS - Anti-vegf therapy ;

Anti-vegf therapy

Anti-vegf therapy
Dermot McGrath
Dermot McGrath
Published: Friday, September 21, 2018
Bridging the gap between clinical trials and real-world outcomes Anti-VEGF agents have revolutionised the treatment of neovascular age-related macular degeneration, significantly reducing AMD-associated blindness and visual impairment in the process, according to Ursula Schmidt-Erfurth MD, PhD, at a special session on the EURETINA Guidelines for Management of Retinal Disease yesterday. Highlighting the achievements and challenges of current anti-VEGF therapy, Dr Schmidt-Erfurth said that intravitreal anti-VEGF therapy has significantly reduced the risk of vision loss in the major retinal diseases. “A miracle happens when we treat with a simple injection of anti-VEGF because a retina can become perfectly normal with this treatment. We know that anti VEGF therapy is beneficial for patients with a rapid, significant and maintained increase in vision and it is also beneficial for the economy given the massive investments involved,” she said. While there has been a significant improvement in therapeutic approaches to the treatment of exudative AMD in recent years, she noted that the impressive benefit of antiangiogenic therapy has not always carried over into real-world scenarios, with outcomes consistently less favourable than clinical trial results. Clinical trials have evaluated fixed one-, two- and three-monthly regimens and flexible PRN and treat-and-extend strategies, noted Dr Schmidt-Erfurth. “Many different approaches and strategies have been tried to bridge this gap between clinical trial data and real-world outcomes but the jury is still out on the optimal number to go before the monthly regimens. No decision has been made yet and there is a request for a global consensus on real world outcome measures to allow greater comparison of results. But this consensus has not been reached yet,” she said.
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Piecing Together a Solution

What is the best use of robotics and AI in cataract and refractive surgery?

Read more...

Advances in Toric IOL Alignment

Biomorphometric approaches offer high precision and increase efficiency.

Read more...

Library of Short Videos Complements Educational Offerings

Read more...

Tackling Waste in Retinal Surgery

Reducing waste from intravitreal injections is an achievable goal.

Read more...

The Modern Era of Refractive Surgery

New technologies for screening and treatment qualify more patients for intervention.

Read more...

Monofocal Plus Finding the Balance

Enhanced monofocals may be the future standard of care in cataract patients.

Read more...

Growing Options Optimise Outcomes in Cataract Surgery

Understanding the promise and potential problems of AI-based IOL formulas.

Read more...

;